Refined ADME Profiles for ATC Drug Classes

<b>Background:</b> Modern generative chemistry initiatives aim to produce potent and selective novel synthetically feasible molecules with suitable pharmacokinetic properties. General ranges of physicochemical properties relevant for the absorption, distribution, metabolism, and excretion (ADME) of drugs have been used for decades. However, the therapeutic indication, dosing route, and pharmacodynamic response of the individual drug discovery program may ultimately define a distinct desired property profile. <b>Methods:</b> A methodological pipeline to build and validate machine learning (ML) models on physicochemical and ADME properties of small molecules is introduced. <b>Results:</b> The analysis of publicly available data on several ADME properties presented in this work reveals significant differences in the property value distributions across the various levels of the anatomical, therapeutic, and chemical (ATC) drug classification. For most properties, the predicted data distributions agree well with the corresponding distributions derived from experimental data across fourteen drug classes. <b>Conclusions:</b> The refined ADME profiles for ATC drug classes should be useful to guide the <i>de novo</i> generation of advanced lead structures directed toward specific therapeutic indications.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-02-28
DOI
https://doi.org/10.3390/pharmaceutics17030308
Citations
4
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
6.02
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Refined ADME Profiles for ATC Drug Classes

Luca Menestrina, Scott Boyer, Jordi Mestres, Ricard García-Serna et al.
4 citations
Pharmaceutics
Computational Drug Discovery Methods
6.02
article

Refined ADME Profiles for ATC Drug Classes

Luca Menestrina, Scott Boyer, Jordi Mestres, Ricard García-Serna, Ismael Gómez, Raquel Parrondo-Pizarro
article en
4 citations

Abstract

<b>Background:</b> Modern generative chemistry initiatives aim to produce potent and selective novel synthetically feasible molecules with suitable pharmacokinetic properties. General ranges of physicochemical properties relevant for the absorption, distribution, metabolism, and excretion (ADME) of drugs have been used for decades. However, the therapeutic indication, dosing route, and pharmacodynamic response of the individual drug discovery program may ultimately define a distinct desired property profile. <b>Methods:</b> A methodological pipeline to build and validate machine learning (ML) models on physicochemical and ADME properties of small molecules is introduced. <b>Results:</b> The analysis of publicly available data on several ADME properties presented in this work reveals significant differences in the property value distributions across the various levels of the anatomical, therapeutic, and chemical (ATC) drug classification. For most properties, the predicted data distributions agree well with the corresponding distributions derived from experimental data across fourteen drug classes. <b>Conclusions:</b> The refined ADME profiles for ATC drug classes should be useful to guide the <i>de novo</i> generation of advanced lead structures directed toward specific therapeutic indications.

PharmaceuticsVol. 17(3)
Universitat de Girona (ES), Thrombotargets (Spain) (ES)
Openalex Percentile: Top 4%
Computational Drug Discovery Methods
6.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Refined ADME Profiles for ATC Drug Classes — Luca Menestrina, Scott Boyer, et al. · Pharmaceutics (2025) | TGRS Research Map | TGRS